Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corpitenib
- Development stage
- Preclinical
- Lead developer
- EnhancedBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Corpitenib (ENB301) is an orally bioavailable small molecule inhibitor targeting SERTA domain-containing protein 1 (SERTAD1). It is being developed by EnhancedBio as an antineoplastic agent for the treatment of colorectal cancer. The drug acts by inhibiting SERTAD1 protein function, which may play a role in tumorigenesis. As of August 2023, corpitenib was in preclinical development for colorectal cancer[1][2][4].
- Other names
- corpitenibENB 301ENB301ENB-301
02
Targets
SERTAD1 (SERTA domain-containing protein 1)
Beyond the preview
Go deeper on corpitenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corpitenib.